Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
about
Lenalidomide and chronic lymphocytic leukemiaImmune reconstitution in chronic lymphocytic leukemiaImmunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaDiscovering Outliers of Potential Drug Toxicities Using a Large-scale Data-driven ApproachA phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesSafety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Advances in treating chronic lymphocytic leukemiaBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioTransplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Teratogenic effects of thalidomide: molecular mechanisms.Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaChronic lymphocytic leukemia: treatment options for patients with refractory disease.Initial testing of lenalidomide by the pediatric preclinical testing programReduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.Lenalidomide in the treatment of chronic lymphocytic leukemia.Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.Pharmacokinetics and tissue disposition of lenalidomide in mice.Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myelomaChronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsE(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunctionTreatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.Modern concepts in the treatment of chronic lymphocytic leukemia.
P2860
Q26823597-986A59A1-9C1F-4ECC-AE7A-28ED5FCDA718Q26865561-AC2052CE-D692-45A3-A42D-D1A43B1EBF2BQ27001318-D9889E5F-100E-4B5A-B514-65C2A2658714Q31140868-4B6319D2-DC29-449E-8279-A1C3E318B01CQ33391895-B27D881E-8865-4B44-AB2D-8D0054423248Q33406478-CF97FB34-F2EC-4265-A2DB-2B643105220BQ33423873-3A7029A8-1FEF-4C20-B8D3-67157517023CQ33429161-00A58AA1-A528-40D6-A354-0F89782C8BD7Q33780253-BFFA28A0-17BC-41C9-9800-3FDC525C14A5Q33796183-DD6332BA-EDAB-47FD-8092-0EC6B5C73234Q34019917-43511C35-DBF4-4FBD-BDE9-357FC7861398Q34026194-B5A9B2DD-2DB2-4980-BA71-A47883670294Q34137016-8269C6EB-7E6F-4AAE-A5BB-136EDEB31232Q34202277-7402B8B6-6340-4EFB-B5C7-DFDF784120C5Q34625543-4D37DA84-9A29-4298-A981-C43EFB3D3A9CQ34660391-23419171-292D-49B3-85CD-AC5FB870A953Q34666858-C6C13C38-1D10-4795-95EF-16B389DBA78CQ34923824-EC3AF600-2FED-4924-B76E-8388B0D60BB2Q35033519-6C9EE28A-131E-4465-AFE0-C93349CD3DF8Q35382716-476CB71F-450F-40DE-B6A6-CBF512D8D53AQ35861457-36DEAA15-306D-4B68-AE4D-75CEEBB66300Q36003724-F60B1B7E-B6F0-43C3-97DC-3EE97E99E980Q36010202-A4B9CFDE-DA56-4E11-86C3-9B2EB4DE5BC6Q36125070-DB6CB003-70CB-461E-BFE6-FCA40894D9EEQ36149549-689661AE-D613-4D39-8A3C-2881C253049DQ36331493-F13A7021-59E2-4421-8B8D-A957A558C158Q36394469-B3DFD096-7FF5-4A49-BDE7-434BB9BCC1FEQ36712736-EA0EB4EB-EF12-4882-BE3D-9E69F213A674Q36744385-946E7193-0AAD-4F08-8425-EEA38634C442Q36862781-A56AAF81-1576-4F35-94C1-4153B4610B76Q36920412-F1C24D18-6BD3-4967-ACC1-E3C42C2CB15BQ36929831-4BF0C3EF-1296-43C0-B309-CED3AE8DC2E2Q36965455-51AAFEE5-E6C7-4E44-A310-4619BF024E23Q37003558-B2C74D42-6E79-486F-9D25-63D2F6FE3D9AQ37159065-AB652D31-C493-45CD-AB33-4C99F55E26F3Q37318762-D808CF93-61A0-4047-BF7B-17DD9CFA9AF7Q37334965-3A9E269A-329B-4F96-9F48-BC1CC2B66FA2Q37418477-EC5E7804-DB44-481D-9DF5-FC3B0594C2A5Q37591411-213115A8-C261-453D-9505-E090DF8B2AB9Q37618337-0F3C82C7-B58F-4F99-83C4-6EE8D55558F5
P2860
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Higher doses of lenalidomide a ...... chronic lymphocytic leukemia.
@ast
Higher doses of lenalidomide a ...... chronic lymphocytic leukemia.
@en
type
label
Higher doses of lenalidomide a ...... chronic lymphocytic leukemia.
@ast
Higher doses of lenalidomide a ...... chronic lymphocytic leukemia.
@en
prefLabel
Higher doses of lenalidomide a ...... chronic lymphocytic leukemia.
@ast
Higher doses of lenalidomide a ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P356
P1476
Higher doses of lenalidomide a ...... chronic lymphocytic leukemia.
@en
P2093
Amy J Johnson
Amy Lehman
Amy S Ruppert
Chelsey A Raymond
Cheryl Kefauver
Ching-Shih Chen
Da-Sheng Wang
David Jarjoura
Farrukh Awan
Gerard Lozanski
P2860
P304
P356
10.1200/JCO.2007.13.9709
P407
P50
P577
2008-04-21T00:00:00Z